Trial results

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

NCT07613307 on ClinicalTrials.gov · last registry update 2026-08-21

A small phase 3 — 130 participants, against a typical 424. Due to report May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1C (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for type 2 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

130

Started

2026-07-15

Primary completion

2027-05 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Hemoglobin A1C (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2 · Diabetes Melletus · Glucose Metabolism Disorders · Metabolic Disorders · Nutritional and Metabolic Diseases · Endocrine System Diseases · Feeding Behavior · Behavior · Fasting · Glucagon-Like Peptide-1 Receptor · Glucagon-Like Peptide Receptors · Receptors, G-Protein-Coupled · Receptors, Cell Surface · Membrane Proteins · Proteins · Receptors, Peptide

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.